Tuesday September 26, 2017
Access Your Account
Covering the whole development process for the global biotechnology industry
Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.
Cell Culture Media
Perfusion Cell Culture
Upstream Contract Services
Upstream Single-Use Technologies
Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.
Downstream Contract Services
Downstream Single-Use Technologies
Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.
Manufacturing Contract Services
Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.
Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.
Pre-Clinical and Clinical Trials
CHT™ Ceramic Hydroxyapatite: A Powerful Tool for Process Development
Accurate, Reproducible, and Standardized Cell Counting and Viability Analysis
Take the Laboratory to the Sample: Implementing PAT with Miniature Modular Technology
Holistic Solutions Available as Single Parts
Pilot to Production: Scaleable Powdered Media Manufacturing
Services from a Single Source: Creating an Alliance for Success
Vaccine Manufacturing Case Study
Parallel Systems for Unparalleled Results
Save Time, Gain Confidence with Single-Use Validation
Expanding CGMP Facilities to Meet Heightened Demand for Plasmid DNA Based Vaccine Therapeutics